Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the ...

Design Therapeutics Inc (DSGN) reports encouraging advancements in their RESTORE-FA trial, with key data expected later this year, despite early-stage challenges.

Detailed price information for Design Therapeutics Inc (DSGN-Q) from The Globe and Mail including charting and trades.

As of December 21, 2025, the average one-year price target for Design Therapeutics is $11.98/share. The forecasts range from a low of $7.07 to a high of $15.75. The average price target represents an ...

) has been revised to $8.50 / share. This is an increase of 13.64% from the prior estimate of $7.48 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...